Thu, Nov 27, 2014, 4:03 PM EST - U.S. Markets closed for Thanksgiving Day


% | $
Quotes you view appear here for quick access.

Vera Bradley, Inc. Message Board

gswkool 79 posts  |  Last Activity: Nov 26, 2014 12:17 PM Member since: Jan 2, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    PSDV presenting

    by gswkool Nov 26, 2014 11:07 AM
    gswkool gswkool Nov 26, 2014 12:17 PM Flag

    from graphing comparison btw ALIM and PSDV they have both moved up almost in tandem, although ALIM has not moved quite as strongly. IMO I think the move is nothing specific to PSDV outside of oversold condition for both stocks.....

  • Reply to

    do not get caught in this trap

    by widearthur Nov 6, 2014 1:04 PM
    gswkool gswkool Nov 26, 2014 12:10 PM Flag

    try using limit orders and breaking up your sell orders into one or two hundred share chunks executed over time....that is if you really want to unload your shares .....btw we could have small cap rally in January...GLTA

  • Reply to

    after hours and premarket trading

    by ligas3 Nov 25, 2014 9:19 PM
    gswkool gswkool Nov 26, 2014 12:00 PM Flag

    Should the markets ever close? With electronic trading is an artifical open and close an antiquated concept? ...although I suppose some of us humans need some sleep....

  • Reply to

    The State of Things

    by ackerjl Nov 25, 2014 2:13 PM
    gswkool gswkool Nov 26, 2014 11:52 AM Flag

    good summary - i took my tax selling loss - will continue to follow the company -not sure if i will invest again -i held a basket of stem cell stocks and they have been a disappointment so far - i do believe ultimately stem cells will play a big role in medicine - just hard to determine who will be winners and losers -

  • Reply to

    Key opinion webcast Dec 1st after the bell

    by lenmac08 Nov 26, 2014 7:45 AM
    gswkool gswkool Nov 26, 2014 11:46 AM Flag

    big pharma is not going to be manipulated - so - why try so hard?

  • gswkool by gswkool Nov 26, 2014 11:07 AM Flag

    at LD Micro conference......maybe we'll finally find out what's actually going on....I hope so....

  • Reply to

    Key opinion webcast Dec 1st after the bell

    by lenmac08 Nov 26, 2014 7:45 AM
    gswkool gswkool Nov 26, 2014 10:39 AM Flag

    They are trying toooo hard - why do they need to try so hard? Big pharma can analyze the data and judge for themselves........trying to put lipstick on a pig - data was inconclusive - waste of time dog and pony show....wait until the data is all out and then speak to it......

  • takes big $. NBS will need to find a partner to take their drug into PIII. Does it matter what small investor thinks of the results? Does the CEO letter expressing big disappointment to the reaction of the market serve a purpose? The big pharmas/biotechs can/will analyze the data/results on their own. How do I interpret all this? IMO the data was not strong enough to reach an inflection point whereby they can attract a suitor. So they are left trying to buoy their stock price as they will need to raise more $$$ to run additional clinical phases before a PIII. Better results down the road may attract a suitor and on better terms. Failure and, well, they are in trouble....IMHO....GLTA

  • maybe that's why the heavy volume? all the funds want to show how smart they are by buying a winner and adding it to their portfolio - too bad they did not buy it when it was in the dog house and many lost faith.....

  • Reply to

    why next year could be a better year

    by gswkool Nov 10, 2014 10:12 AM
    gswkool gswkool Nov 24, 2014 1:04 PM Flag

    if i remember correctly, one of the drugs furthest along in their pipeline suffered a setback. That was some time ago. I'm losing track of things, - with the biotech sector doing so well, this one has been a disappointment. however, as long as they don't have to dilute their shares too much and are able to keep plugging along, - we could still get lucky if one of the drugs in their pipeline hits and a big pharma/biotech takes an interest. this company does not have the capital to develop beyond early phases. they choose not to anyway -that is not their business model. the celiac treatment looks interesting - hoping results are good and they can entice a big company to partner up with them. they also have an allergy drug candidate that looks interesting but that is pre-clinical. .....GLTA

  • Reply to

    Pfizer Latanoprost glaucoma

    by billygbillyg Nov 20, 2014 8:33 PM
    gswkool gswkool Nov 21, 2014 10:52 AM Flag

    Mick, not sure what the new cash has to do with emphasis on glaucoma....if PFE were to press forward, wouldn't they be the ones hopefully funding development? I would hope so. And I certainly wouldn't want to see PSDV going it alone. They already are spending on wholly owned Medidur trial. I hope they are conservative and keep ample cash cushion -...............

  • gswkool gswkool Nov 20, 2014 10:55 AM Flag

    Stock is clearly in the doghouse and so far has been one of my worst investments. But that is the way of biotech. I bought GERN when it was in doghouse with one drug left in its pipeline - imeltestat. My investment sank after FDA put clinical hold on it due to elevated liver enzymes. I bought more shares. After several months, hold was lifted and shortly thereafter a unit of JNJ made $950M deal with GERN. Now I'm in the black, making money. So... looking at the BLRX pipeline - do you think any of BLRX drugs in clinic have a shot? I think the Celiac treatment is interesting. They have other drugs so you have multiple shots on goal. Call me crazy, but I recently purchased more shares and intend to buy additional. .......maybe I should attend gambler's anonymous......anyhow....GLTA

  • Reply to

    Why the drop?

    by engelcameron14 Nov 17, 2014 5:28 PM
    gswkool gswkool Nov 17, 2014 5:50 PM Flag

    I'm a stock holder and not impressed with their writeup of results. Is 14M some kind of magic number? Imaging could see no difference. How many stem cells do you have to inject before it makes a difference? Less than 14M makes no difference but greater than 14M does...what does that mean? the only thing I can say is that maybe it takes definitively more {20M+} before seeing good results - another 6M and that does it? It is possible there is some quantity that will be sufficient to statistically get big enough improvement in large trial to be FDA approved? only time will tell -certainly not this study...

  • gswkool gswkool Nov 17, 2014 3:00 PM Flag

    One thing i'll say is that Teva has done an excellent job of the time all is said and done, with all the legal maneuvering, - it won't matter. AS you say, the patent expires Sept 2015 and here we are almost EOY 2014.......

  • Reply to

    why next year could be a better year

    by gswkool Nov 10, 2014 10:12 AM
    gswkool gswkool Nov 17, 2014 9:44 AM Flag

    the celiac treatment looks interesting, but the stock price performance has been atrocious...this company simpy gets no respect. Bought another 1000 shares and hoping that it recovers next year with some positive clinical news and partnership activity. if not, i gotta consider taking a loss...

  • opinions, anyone? Incyte I believe owns Jakafi US right outright. GERN gets milestones and royalties. GERN drug may be much more effective. Jakafi Revenue I believe projected to be $350-400M over the next year. Anyone have a handle - ? I would think they will get bought out eventually -the deal shares risks between the twoo parties and has opt out clauses. If it's taken through to approval, what is long term valuation & buyout price?

    Sentiment: Buy

  • gswkool by gswkool Nov 13, 2014 6:32 PM Flag

    is about as big as state of Ohio ....nice that they got an approval but it won't move the needle. What about large Asian countries? China? India? Just wondering -

  • Reply to

    New investor in CDTI

    by gswkool Nov 10, 2014 10:20 AM
    gswkool gswkool Nov 10, 2014 11:02 AM Flag

    the markets are a casino....anyone in them is gambling....this stock is just higher up the risk chain. some people don't have the stomach for the markets or risk - for those people they should stay away. you're right in that respect.....

  • gswkool gswkool Nov 10, 2014 10:44 AM Flag

    it could. they could come out with an announcement two days fromn ow. it could also be because they are having issues. it could be because they don't know what the actual status is. i can only go by my impression - which is that the company is generally forthcoming with news of a material nature when they have it. Things outside their control I get the impression they mask that lack of control with excuses like "for competitive reasons" or general statements like "we are excited by continued progess". When i listened to CC, there was one part in QA where CEO was asked about pre-clinical stuff and in his response he mentioned about dealing with changing personnel at partner companies. I think the partners are in control with pre-clinical stuff and there may be issues with follow through and prioritization of projects over time, with changing cast of characters. I'm willing to give things some time and hope for best because from my view the SP excludes pre-clinical potential and the company has ample cash to last a few years without dilution. I'm just gonna be patient and hope things pan out -which is maybe all PSDV can do with thinkgs outside its control.....

  • gswkool gswkool Nov 10, 2014 10:25 AM Flag

    they may be confident, -imo i think supreme court will decide in favor of MNTA ... i believe they've heard the arguments and were kinda split ......wondering when they will announce a decision....

21.99-0.14(-0.63%)Nov 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.